Navigation Links
Marrone Bio Innovations Files Patent for a Unique Bacillus Species
Date:3/27/2013

Davis, CA (PRWEB) March 27, 2013

Marrone Bio Innovations, Inc. (MBI) a leading global provider of natural pest management products for the agricultural and water treatment markets, announces the submission of a patent application encompassing a new Bacillus sp. strain F727, to the United States Patent and Trademark Office. This strain was first discovered from soil collected in California by one of MBI’s employees. The chemistry and genetic profiles appear to be unique from other known Bacillus species. In addition, the anti-fungal compounds produced by this new strain are different than the current commercial Bacillus biofungicide products.

In comparison tests with commonly used chemical fungicides, the Bacillus sp. strain F727 shows a high level of activity against a broad range of fungal and bacterial plant pathogens. In MBI’s greenhouse tests, Bacillus strain F727 outperformed the leading Bacillus biofungicides on the market, particularly on downy mildews, which are difficult to control with both chemicals and biofungicides.

According to Phyllis Himmel, Ph.D., MBI Vice President of Research & Development, Bacillus sp. strain F727 shows consistent fungicidal activity against Botrytis gray mold and downy mildews in plant tests. “We are excited to move this candidate to field trials on a broad range of crops in 2013,” she said. “The strain has also shown activity beyond plant disease control. Additional work is in progress to explore its usefulness as a plant growth promoter in crops such as corn, soybeans, tomatoes and turf.”

Hector Absi, MBI’s Sr. VP of Commercial Operations, stated, “I am excited to have another MBI fungicide/bactericide to enhance our current commercial product, Regalia®. We believe the combination of the two products will provide superior disease control and plant health across a broad range of crops.”

###

About Marrone Bio Innovations
Marrone Bio Innovations, Inc. (MBI) is a leading global provider of biopesticides for the agricultural and water treatment markets. MBI's award-winning products include Regalia® biofungicide, Grandevo®, a broad-spectrum bioinsecticide and Zequanox® the first biological product to selectively control invasive zebra and quagga mussels. MBI has also developed a pipeline of products including several nematicide, fungicide, algaecide and plant health product candidates. The company currently has more than 150 patents pending in the U.S. and internationally.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10577112.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Marrone Bio Innovations Submits New Bioherbicide for EPA Registration
2. Marrone Bio Innovations’ Zequanox® Demonstrates Control of Zebra Mussels in Illinois Lake
3. Marrone Bio Innovations’ CEO to Address European Biopesticide Industry at Informa Life Sciences Biopesticides Conference
4. Marrone Bio Innovations Breaks Ground on Michigan Manufacturing Facility
5. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
6. BioHealth Innovation, Inc. Forms Commercial Relevance Advisory Board to Help Advance Market-Relevant Innovations in Central Maryland
7. Genomic Health Announces Results from Two Studies Demonstrating Innovations in Next Generation Sequencing From Paraffin Tissue, Enhancing Understanding of Tumor Biology
8. Brain Research Foundation 2013 Scientific Innovations Awards To Dr. Jean Hebert and Dr. Brian Litt
9. Prism Awards Honor Innovations in ‘Ubiquitous’ Photonics Technology
10. LATISTA Announces Next-Generation iPad App 2.0 for Construction with Industry Leading Innovations
11. Wake Forest Innovations Partners with Veterinary Bioscience Institute to Develop Educational Programs for Life Science Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
Breaking Biology News(10 mins):